Vanda Pharmaceuticals Inc (VNDA)
4.875
+0.20
(+4.17%)
USD |
NASDAQ |
May 03, 16:00
5.05
+0.18
(+3.59%)
After-Hours: 19:43
Vanda Pharmaceuticals Research and Development Expense (Quarterly): 24.34M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 24.34M |
| September 30, 2023 | 16.60M |
| June 30, 2023 | 16.65M |
| March 31, 2023 | 19.24M |
| December 31, 2022 | 18.45M |
| September 30, 2022 | 24.86M |
| June 30, 2022 | 21.49M |
| March 31, 2022 | 20.97M |
| December 31, 2021 | 19.33M |
| September 30, 2021 | 19.65M |
| June 30, 2021 | 20.25M |
| March 31, 2021 | 16.13M |
| December 31, 2020 | 14.85M |
| September 30, 2020 | 12.30M |
| June 30, 2020 | 12.90M |
| March 31, 2020 | 15.53M |
| December 31, 2019 | 13.07M |
| September 30, 2019 | 11.35M |
| June 30, 2019 | 10.95M |
| March 31, 2019 | 13.28M |
| December 31, 2018 | 12.92M |
| September 30, 2018 | 11.39M |
| June 30, 2018 | 9.866M |
| March 31, 2018 | 9.416M |
| December 31, 2017 | 10.15M |
| Date | Value |
|---|---|
| September 30, 2017 | 10.18M |
| June 30, 2017 | 7.648M |
| March 31, 2017 | 10.57M |
| December 31, 2016 | 7.614M |
| September 30, 2016 | 7.294M |
| June 30, 2016 | 6.70M |
| March 31, 2016 | 7.548M |
| December 31, 2015 | 8.747M |
| September 30, 2015 | 9.974M |
| June 30, 2015 | 5.946M |
| March 31, 2015 | 4.478M |
| December 31, 2014 | 4.751M |
| September 30, 2014 | 3.701M |
| June 30, 2014 | 3.514M |
| March 31, 2014 | 7.263M |
| December 31, 2013 | 6.269M |
| September 30, 2013 | 8.022M |
| June 30, 2013 | 6.10M |
| March 31, 2013 | 8.111M |
| December 31, 2012 | 10.94M |
| September 30, 2012 | 10.16M |
| June 30, 2012 | 12.49M |
| March 31, 2012 | 12.18M |
| December 31, 2011 | 10.56M |
| September 30, 2011 | 8.174M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.95M
Minimum
Jun 2019
24.86M
Maximum
Sep 2022
17.31M
Average
16.65M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| ADMA Biologics Inc | 0.4455M |
| INVO Bioscience Inc | 0.0059M |
| Johnson & Johnson | 3.542B |
| Nektar Therapeutics | 29.94M |
| Invivyd Inc | 62.26M |